Thus in this study, fusing of human antibody HN3 with epithelial cell-derived exosomes was examined to give an improved tumor targeting efficiency as GPC3 is specifically over expressed in liver cancer cells and also to warrant a safe, efficient delivery platform of CRISPR-Cas9, an effective gene editing tool. The gene discussed is GPC3; the disease is liver cancer.